Physician profile
Daniel Eugene Williams
NPI 1508809252
$1,351.62
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $97.30 · 2021: $156 · 2022: $24.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $168.96 | 2019 | |
| Rigel Pharmaceuticals, INC. | $156.51 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $131.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $125.71 | 2019-2022 | |
| Seagen INC. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $89.74 | 2019 | |
| Janssen Biotech, INC. | $77.69 | 2019-2020 | |
| Tesaro, INC. | $59.12 | 2019 | |
| Amgen INC. | $40.39 | 2019 | |
| Taiho Oncology, INC. | $39.86 | 2019 | |
| Grifols USA, LLC | $35.02 | 2019 | |
| Genzyme Corporation | $34.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.01 | 2019 | |
| Celgene Corporation | $30.49 | 2019 | |
| Array Biopharma INC | $30.48 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $26.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.26 | 2019 | |
| Daiichi Sankyo INC. | $17.08 | 2019 | |
| Incyte Corporation | $16.89 | 2019 | |
| Pfizer INC. | $16.31 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.14 | 2019 | |
| Glaxosmithkline, LLC. | $16.05 | 2020 | |
| Mylan Institutional INC. | $15.72 | 2019 | |
| Lilly USA, LLC | $13.39 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $12.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.